Astrazeneca and Daiichi’s big reveal disappoints
High level results on datopotamab raise safety and efficacy concerns, putting billion-dollar sales forecasts at risk.
Spotlight − late-stage challengers in Parkinson’s disease
Biogen and Denali stand out among small developers targeting Parkinson's.
Archer misses the target
Annexon’s failure in geographic atrophy could clear the way for its rivals.